尽管 Anthropic 负责人 Dario Amodei 呼吁放缓人工智慧发展，Ozempic 制造商 Novo Nordisk 仍加速推进与该人工智慧公司的合作。Novo 正与 Anthropic 的 Claude Science 合作以加速药物研发，执行长 Mike Doustdar 指出此举将强化研发能力，并期望让公司成为全球最具人工智慧驱动力的医疗保健企业。在此之前，Novo 已运用 Claude 将临床研究报告、设备协议与病患指南自动化。
Novo 对提速具有迫切需求，因其重磅药物 Ozempic 与 Wegovy 的关键成分司美格鲁肽（Semaglutide）预计最快于下一个十年初期（约 5 年后）在欧美面临廉价学名药竞争。鉴于次世代药物研发管线经历多起备受瞩目的挫折，5 年在药物研发领域可谓转瞬即逝。此外，Novo 亦与 OpenAI 展开合作，将人工智慧技术导入制造、商业运营部门以及研发领域。
制药业与人工智慧企业正加速合作布局。今年稍早，Anthropic 与 Bristol-Myers Squibb 签署了广泛协议；Google 旗下的 Isomorphic Labs 亦与 Novartis 及 Novo 的主要对手 Eli Lilly 展开合作。正如 Dario Amodei 于周三所述，人工智慧最终可能将长达 100 年的生物医学突破压缩至 10 年内完成，突显出企业在潜在风险警告下，仍因庞大的务实利益积极拥抱该技术。
Even as Anthropic chief Dario Amodei urges a slowdown in artificial intelligence progress, Ozempic producer Novo Nordisk is accelerating collaboration with the firm. Novo is partnering with Anthropic's Claude Science to expedite drug development, which CEO Mike Doustdar stated will significantly boost research capabilities toward becoming the leading AI-driven healthcare entity. Novo previously utilized Claude to automate clinical trial reports, device procedures, and patient documentation.
The urgency reflects looming patent expirations; semaglutide, the active ingredient in Ozempic and Wegovy, faces low-cost generic rivalry in Europe and the United States by early next decade, roughly 5 years away. That 5-year timeline is narrow in pharmaceutical timelines, particularly following several major pipeline setbacks for next-generation treatments. Consequently, Novo is simultaneously integrating OpenAI systems across manufacturing, commercial, and research operations.
Wider pharmaceutical partnerships are rapidly proliferating across the sector. Earlier this year, Anthropic finalized an expansive agreement with Bristol-Myers Squibb, while Google's Isomorphic Labs partnered with Novartis and major obesity competitor Eli Lilly. As Dario Amodei observed, artificial intelligence holds the potential to compress 100 years of biological advancements into a single 10-year span, driving commercial adoption despite widespread developmental cautions.